ASCO 2014 - Featured Videos

Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive mPrCa

Details
ASCO 2014 - Impact on Overall Survival (OS) with Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive Newly Metastatic Prostate Cancer (mPrCa): An ECOG-led Phase III Randomized Trial Christopher Sweeney, MD Dana-Farber Cancer Institute SEE RELATED CONTENT Read an exclusive report by a UroToday medical writer View a slide presentation by Dr. Sweeney Insights into E3805: The CHAARTED tri...